{"result": "{\n    \"title\": \"Breast Cancer Community\",\n    \"summary\": \"The breast cancer community revolves around various entities, including LABC, TAXANE-BASED CHEMOTHERAPY, BEVACIZUMAB, TRYPHAENA, FEC REGIMEN, THP, TCHP, DOCETAXEL, and U.S. FOOD AND DRUG ADMINISTRATION. These entities are interconnected through relationships, such as treatment regimens, clinical trials, and authorship. The community is focused on understanding and combating breast cancer, with a particular emphasis on LABC and IBC.\",\n    \"rating\": 8.0,\n    \"rating_explanation\": \"The impact severity rating is high due to the significant importance of breast cancer research and treatment, as well as the potential for breakthroughs in understanding and combating the disease.\",\n    \"findings\": [\n        {\n            \"summary\": \"LABC and IBC: Key Entities in the Community\",\n            \"explanation\": \"LABC and IBC are two key entities in the breast cancer community. LABC is a type of breast cancer that has spread to the lymph nodes and/or surrounding tissues, while IBC is a type of breast cancer that has spread to the lymph nodes and/or surrounding tissues. Both entities are important in understanding and combating breast cancer. [Data: Entities (94, 203, 166); Relationships (71, 81)]\"\n        },\n        {\n            \"summary\": \"TAXANE-BASED CHEMOTHERAPY and BEVACIZUMAB: Important Treatments\",\n            \"explanation\": \"TAXANE-BASED CHEMOTHERAPY and BEVACIZUMAB are two important treatments in the breast cancer community. TAXANE-BASED CHEMOTHERAPY is a type of chemotherapy used in the treatment of IBC, while BEVACIZUMAB is a monoclonal antibody used in combination with chemotherapy to inhibit tumor growth and metastasis. Both treatments have shown promise in combating breast cancer. [Data: Entities (205, 203); Relationships (81, 198)]\"\n        },\n        {\n            \"summary\": \"TRYPHAENA: A Key Clinical Trial\",\n            \"explanation\": \"TRYPHAENA is a key clinical trial in the breast cancer community. The trial investigated the safety and tolerability of dual anti-HER2 antibodies with different regimens and reported promising results. TRYPHAENA is an important study in understanding and combating breast cancer. [Data: Entities (166); Relationships (212, 209, 210, 211)]\"\n        },\n        {\n            \"summary\": \"FEC REGIMEN and THP: Important Treatment Regimens\",\n            \"explanation\": \"FEC REGIMEN and THP are two important treatment regimens in the breast cancer community. FEC REGIMEN is a chemotherapy regimen used in the treatment of IBC, while THP is a regimen used in combination with FEC REGIMEN. Both regimens have shown promise in combating breast cancer. [Data: Entities (203, 167); Relationships (209, 210)]\"\n        },\n        {\n            \"summary\": \"U.S. FOOD AND DRUG ADMINISTRATION: A Key Regulator\",\n            \"explanation\": \"The U.S. FOOD AND DRUG ADMINISTRATION is a key regulator in the breast cancer community. The agency has approved and withdrawn approval for various treatments, including BEVACIZUMAB, due to safety and efficacy concerns. The FDA plays a crucial role in ensuring the safety and effectiveness of breast cancer treatments. [Data: Entities (223); Relationships (261)]\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n94,\"\"\"LABC\"\"\",\"Based on the provided data, here is a comprehensive summary of the entity \"\"LABC\"\":\n\nLABC, which stands for locally advanced breast cancer, is a type of breast cancer that has spread to the lymph nodes and/or surrounding tissues. It is characterized by high-risk characteristics and is often studied in clinical trials. Specifically, LABC is a type of breast cancer that is locally advanced, meaning it has grown beyond the breast tissue and into surrounding areas, such as the lymph nodes, chest wall, or skin. This type of breast cancer requires specialized treatment and management to effectively manage its progression.\n\nNote: I resolved the contradictions by combining the descriptions that mentioned LABC as a type of breast cancer, and those that mentioned its abbreviation and characteristics. I also removed the duplicate descriptions to provide a concise and coherent summary.\",3\r\n205,\"\"\"TAXANE-BASED CHEMOTHERAPY\"\"\",\"Here is a comprehensive summary of the data:\n\nTaxane-based chemotherapy is a type of chemotherapy used in the treatment of Inflammatory Breast Cancer (IBC). It is used in combination with Bevacizumab to inhibit tumor growth and metastasis.\",2\r\n203,\"\"\"BEVACIZUMAB\"\"\",\"Here is a comprehensive summary of the data:\n\nBevacizumab is a medication used in the treatment of breast cancer, specifically in combination with chemotherapy to treat breast cancer. It is a monoclonal antibody against VEGF, which is used in combination with taxane-based chemotherapy to inhibit tumor growth and metastasis. Bevacizumab is a targeted therapy, used in combination with chemotherapy for patients with inflammatory breast cancer (IBC). It is also a technology used in the treatment of breast cancer, which was studied in the presented research. Additionally, Bevacizumab is a type of cancer treatment and a type of medication used in cancer treatment.\n\nNote: I resolved the contradictions by combining the information from each description to provide a comprehensive summary.\",8\r\n166,\"\"\"TRYPHAENA\"\"\",\"Here is a comprehensive summary of the data:\n\nTRYPHAENA is a clinical trial that investigated the safety and tolerability of dual anti-HER2 antibodies with different regimens. Specifically, it was a randomized phase 2 study that evaluated the safety and tolerability of dual anti-HER2 antibodies combined with NAC (Neoadjuvant chemotherapy). Additionally, TRYPHAENA was also a randomized phase II cardiac safety study. The study reported pCR (Pathological Complete Response) rates, DFS (Disease-Free Survival), and OS (Overall Survival) at the 3-year follow-up.\",10\r\n169,\"\"\"FEC REGIMEN\"\"\",\"Here is a comprehensive summary of the data:\n\nThe \"\"FEC REGIMEN\"\" is a chemotherapy treatment option for patients with Inflammatory Breast Cancer (IBC). It is a chemotherapy treatment protocol designed to provide effective treatment for IBC patients.\",3\r\n167,\"\"\"THP\"\"\",\"Here is a comprehensive summary of the data:\n\nTHP is a chemotherapy treatment protocol specifically designed for treating HER2+ Inflammatory Breast Cancer (IBC). It is a regimen that combines docetaxel, trastuzumab, and pertuzumab, which are used together to treat cancer. This treatment protocol was part of the NeoSphere clinical trial, which reported promising pathological complete response (pCR) rates.\",3\r\n170,\"\"\"TCHP\"\"\",\"Here is a comprehensive summary of the data:\n\nTCHP is a chemotherapy treatment protocol specifically designed for treating HER2+ Inflammatory Breast Cancer (IBC). It is a regimen that combines docetaxel, carboplatin, pertuzumab, and trastuzumab to provide effective treatment for patients with this type of cancer.\",2\r\n129,\"\"\"DOCETAXEL\"\"\",\"Here is a comprehensive summary of the data:\n\nDocetaxel is a chemotherapy drug used in the treatment of breast cancer. It is a chemotherapy regimen mentioned in studies and a treatment option for patients with inflammatory breast cancer (IBC). Additionally, docetaxel is used in combination with epirubicin and trastuzumab in the treatment of breast cancer, and it was also used in the NeoSphere clinical trial. Furthermore, docetaxel is a technology used in clinical trials, indicating its potential for further research and development in the field of breast cancer treatment.\n\nNote: I resolved the contradictions by combining the descriptions that mentioned docetaxel as a chemotherapy drug, treatment option, and technology used in clinical trials, while removing the duplicates and ensuring the summary is coherent and easy to understand.\",3\r\n700,\"\"\"CHIA\"\"\",\"\"\"Chia is an author of a study on cardiac safety in patients with HER2-positive early breast cancer.\"\"\",1\r\n703,\"\"\"ENIU\"\"\",\"\"\"Eniu is an author of a study on cardiac safety in patients with HER2-positive early breast cancer.\"\"\",1\r\n702,\"\"\"HARVEY\"\"\",\"\"\"Harvey is an author of a study on cardiac safety in patients with HER2-positive early breast cancer.\"\"\",1\r\n701,\"\"\"HICKISH\"\"\",\"\"\"Hickish is an author of a study on cardiac safety in patients with HER2-positive early breast cancer.\"\"\",1\r\n699,\"\"\"SCHNEEWEISS\"\"\",\"\"\"Schneeweiss is an author of a study on cardiac safety in patients with HER2-positive early breast cancer.\"\"\",1\r\n704,\"\"\"WALDRON-LYNCH\"\"\",\"\"\"Waldron-Lynch is an author of a study on cardiac safety in patients with HER2-positive early breast cancer.\"\"\",1\r\n168,\"\"\"FEC\"\"\",\"Here is a comprehensive summary of the data:\n\nFEC is a chemotherapy regimen that has been mentioned in studies, used in clinical trials, and specifically used in the NeoSphere clinical trial. It is a treatment regimen that consists of 5-fluorouracil, epirubicin, and cyclophosphamide. FEC is used in the treatment of breast cancer, and is a type of chemotherapy regimen used in the treatment of inflammatory breast cancer (IBC).\",2\r\n204,\"\"\"VEGF\"\"\",\"\"\"VEGF is a known angiogenesis activator in tumors.\"\"\",1\r\n223,\"\"\"U.S. FOOD AND DRUG ADMINISTRATION\"\"\",\"Here is a comprehensive summary of the data:\n\nThe U.S. Food and Drug Administration (FDA) is an organization that plays a crucial role in the approval and regulation of various medical treatments. In the context of breast cancer, the FDA has taken different actions regarding two specific treatments.\n\nFirstly, the FDA accelerated the approval of atezolizumab in combination with nab-paclitaxel for patients with unresectable or metastatic triple-negative breast cancer. This approval indicates that the FDA deemed these treatments effective and safe for this specific patient population.\n\nOn the other hand, the FDA approved bevacizumab for metastatic breast cancer, but later withdrew approval due to safety and efficacy concerns. This decision suggests that the FDA reevaluated the treatment's benefits and risks and determined that it was no longer suitable for patients with metastatic breast cancer.\n\nOverall, the FDA's actions demonstrate its commitment to ensuring the safety and effectiveness of medical treatments, while also being willing to reevaluate and adjust its decisions as new information becomes available.\",1\r\n130,\"\"\"AC\"\"\",\"Here is a comprehensive summary of the data:\n\nAC is a chemotherapy regimen used in clinical trials, specifically consisting of doxorubicin and cyclophosphamide. It is a regimen of doxorubicin and cyclophosphamide used in cancer treatment, and is a treatment regimen for breast cancer.\n\nNote: I resolved the contradiction between the descriptions that mentioned \"\"technology\"\" and \"\"chemotherapy regimen\"\", as the majority of the descriptions suggest that AC is a chemotherapy regimen, and the mention of technology is likely an error.\",3\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n71,\"\"\"IBC\"\"\",\"\"\"LABC\"\"\",\"\"\"LABC includes IBC, a type of breast cancer with high-risk characteristics.\"\"\",57\r\n81,\"\"\"IBC\"\"\",\"\"\"TAXANE-BASED CHEMOTHERAPY\"\"\",\"\"\"Taxane-based Chemotherapy is used in the treatment of IBC.\"\"\",56\r\n198,\"\"\"TRASTUZUMAB\"\"\",\"\"\"BEVACIZUMAB\"\"\",\"\"\"Bevacizumab is used in combination with Trastuzumab in the studies.\"\"\",23\r\n144,\"\"\"PACLITAXEL\"\"\",\"\"\"BEVACIZUMAB\"\"\",\"\"\"Paclitaxel is used in certain circumstances with bevacizumab for metastatic breast cancer.\"\"\",16\r\n212,\"\"\"TRYPHAENA\"\"\",\"\"\"OVERMOYER ET AL.\"\"\",\"\"\"Overmoyer et al. reported the results of the TRYPHAENA study, which investigated the efficacy of a neoadjuvant treatment for IBC patients.\"\"\",15\r\n209,\"\"\"TRYPHAENA\"\"\",\"\"\"FEC REGIMEN\"\"\",\"\"\"TRYPHAENA evaluated the safety and tolerability of FEC regimen plus pertuzumab and trastuzumab followed by THP.\"\"\",13\r\n210,\"\"\"TRYPHAENA\"\"\",\"\"\"THP\"\"\",\"\"\"TRYPHAENA evaluated the safety and tolerability of FEC regimen plus pertuzumab and trastuzumab followed by THP.\"\"\",13\r\n211,\"\"\"TRYPHAENA\"\"\",\"\"\"TCHP\"\"\",\"\"\"TRYPHAENA evaluated the safety and tolerability of docetaxel and carboplatin plus pertuzumab and trastuzumab (TCHP).\"\"\",12\r\n186,\"\"\"DOCETAXEL\"\"\",\"\"\"BEVACIZUMAB\"\"\",\"\"\"Bevacizumab is used in combination with Docetaxel in the studies.\"\"\",11\r\n221,\"\"\"FEC REGIMEN\"\"\",\"\"\"BEVACIZUMAB\"\"\",\"\"\"Bevacizumab is used in combination with FEC regimen in the BEVERLY-1 study to treat IBC patients with HER2- disease.\"\"\",11\r\n214,\"\"\"TRYPHAENA\"\"\",\"\"\"CHIA\"\"\",\"\"\"Chia is an author of the TRYPHAENA study, which is a randomized phase II cardiac safety study.\"\"\",11\r\n217,\"\"\"TRYPHAENA\"\"\",\"\"\"ENIU\"\"\",\"\"\"Eniu is an author of the TRYPHAENA study, which is a randomized phase II cardiac safety study.\"\"\",11\r\n216,\"\"\"TRYPHAENA\"\"\",\"\"\"HARVEY\"\"\",\"\"\"Harvey is an author of the TRYPHAENA study, which is a randomized phase II cardiac safety study.\"\"\",11\r\n215,\"\"\"TRYPHAENA\"\"\",\"\"\"HICKISH\"\"\",\"\"\"Hickish is an author of the TRYPHAENA study, which is a randomized phase II cardiac safety study.\"\"\",11\r\n213,\"\"\"TRYPHAENA\"\"\",\"\"\"SCHNEEWEISS\"\"\",\"\"\"Schneeweiss is an author of the TRYPHAENA study, which is a randomized phase II cardiac safety study.\"\"\",11\r\n218,\"\"\"TRYPHAENA\"\"\",\"\"\"WALDRON-LYNCH\"\"\",\"\"\"Waldron-Lynch is an author of the TRYPHAENA study, which is a randomized phase II cardiac safety study.\"\"\",11\r\n260,\"\"\"BEVACIZUMAB\"\"\",\"\"\"TAXANE-BASED CHEMOTHERAPY\"\"\",\"\"\"Bevacizumab is used in combination with taxane-based chemotherapy to inhibit tumor growth and metastasis.\"\"\",10\r\n220,\"\"\"FEC\"\"\",\"\"\"BEVACIZUMAB\"\"\",\"\"\"Bevacizumab is used in combination with FEC in the studies.\"\"\",10\r\n259,\"\"\"BEVACIZUMAB\"\"\",\"\"\"VEGF\"\"\",\"\"\"Bevacizumab is a monoclonal antibody against VEGF, a known angiogenesis activator in tumors.\"\"\",9\r\n261,\"\"\"BEVACIZUMAB\"\"\",\"\"\"U.S. FOOD AND DRUG ADMINISTRATION\"\"\",\"\"\"U.S. Food and Drug Administration approved and withdrew approval for bevacizumab due to safety and efficacy concerns.\"\"\",9\r\n187,\"\"\"AC\"\"\",\"\"\"THP\"\"\",\"\"\"AC and THP are regimens used in cancer treatment.\"\"\",6\r\n148,\"\"\"LABC\"\"\",\"\"\"AC\"\"\",\"\"\"AC is a chemotherapy regimen used in the treatment of LABC patients.\"\"\",6\r\n184,\"\"\"DOCETAXEL\"\"\",\"\"\"AC\"\"\",\"\"\"docetaxel and AC are technologies used together in clinical trials.\"\"\",6\r\n185,\"\"\"DOCETAXEL\"\"\",\"\"\"FEC REGIMEN\"\"\",\"\"\"FEC regimen is used in combination with Docetaxel in the BEVERLY-1 study to treat IBC patients with HER2- disease.\"\"\",6\r\n147,\"\"\"LABC\"\"\",\"\"\"FEC\"\"\",\"\"\"FEC is a chemotherapy regimen used in the treatment of LABC patients.\"\"\",5\r\n219,\"\"\"THP\"\"\",\"\"\"TCHP\"\"\",\"\"\"THP and TCHP are regimens used in cancer treatment.\"\"\",5\r\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "llama3-8b-8192", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": null}}